Biotech Values

[genisi]

Bear in mind that final data from the simeprevir+sofosbuvir combo are yet to report in early 2014 and we still need to see SVR12 in cohort 2, plus the number of patients receiving 12 weeks treatment is just about 40 in each arm. I do expect docs to want to treat patients with simeprevir+sofosbuvir off label but think just the more advanced ones, and I honestly don't see how they will overcome reimbursement issue.